Moderna, Inc. Share Price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:08:11 13/06/2024 am IST 5-day change 1st Jan Change
149.8 USD +0.93% Intraday chart for Moderna, Inc. -3.14% +50.81%
Sales 2024 * 416.71Cr 35TCr Sales 2025 * 484.42Cr 40TCr Capitalization 5.69TCr 4,74300Cr
Net income 2024 * -268Cr -22TCr Net income 2025 * -201.7Cr -17TCr EV / Sales 2024 * 12.1 x
Net cash position 2024 * 625.02Cr 52TCr Net cash position 2025 * 394.02Cr 33TCr EV / Sales 2025 * 10.9 x
P/E ratio 2024 *
-21.1 x
P/E ratio 2025 *
-28.4 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.43%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.86%
1 week-3.14%
Current month+5.21%
1 month+19.34%
3 months+35.81%
6 months+92.18%
Current year+50.81%
More quotes
1 week
142.27
Extreme 142.27
158.82
1 month
119.03
Extreme 119.03
170.47
Current year
84.06
Extreme 84.06
170.47
1 year
62.55
Extreme 62.55
170.47
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 01/11/01
Director of Finance/CFO 47 06/22/06
President 48 01/13/01
Members of the board TitleAgeSince
Director/Board Member 65 01/18/01
Director/Board Member 74 01/20/01
Director/Board Member 67 11/19/11
More insiders
Date Price Change Volume
12/24/12 149.6 +0.80% 2 117 274
11/24/11 148.4 -0.13% 1,924,981
10/24/10 148.6 -1.60% 5,969,563
07/24/07 151 -2.38% 2,521,599
06/24/06 154.7 -0.10% 3,373,486

Delayed Quote Nasdaq, June 12, 2024 at 11:53 pm IST

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.4 USD
Average target price
145.2 USD
Spread / Average Target
-2.17%
Consensus